iShares Genomics Immunology and Healthcare ETF
IDNA
65 hedge funds and large institutions have $85.8M invested in iShares Genomics Immunology and Healthcare ETF in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 5 closing their positions.
770% more capital inflows, than outflows
Capital inflows: $14.5M | Capital outflows: $1.67M
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
8% more funds holding
Funds holding: 60 → 65 (+5)
5.32% more ownership
Funds ownership: 40.91% → 46.23% (+5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$3.45M |
| 2 |
TF
Trek Financial
Scottsdale,
Arizona
|
+$2.73M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$2.11M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.1M |
| 5 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTS Securities
Miami,
Florida
|
-$677K |
| 2 |
Morgan Stanley
New York
|
-$386K |
| 3 |
PCA
Prosperity Capital Advisors
Westlake,
Ohio
|
-$106K |
| 4 |
CCA
Clearwater Capital Advisors
Hoffman Estates,
Illinois
|
-$102K |
| 5 |
FFA
Founders Financial Alliance
Raleigh,
North Carolina
|
-$99.1K |
IDNA Hedge Fund Activity: Q2 2026 in Review
65 of the 8,355 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q2 2026, worth a combined $85.8M — up 39% from $61.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IDNA positions and 5 closed out — a net gain of 7 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $3.45M. The largest seller was GTS Securities, exiting entirely with an estimated $677K sold.
- 65 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q2 2026, up from 60 in Q1 2026.
- Funds reported $85.8M of iShares Genomics Immunology and Healthcare ETF stock for Q2 2026, up 39% quarter-over-quarter.
- 12 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q2 2026 and 5 closed out, a net change of +7 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q2 2026 was Jane Street, an estimated $3.45M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q2 2026 was GTS Securities, an estimated $677K sold.
Based on aggregated 13F filings for Q2 2026.